Advertisement

Index by author

March 01, 1995; Volume 23,Issue 3

B

  1. Benet, L Z

    1. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry.
      A Ding, P Zia-Amirhosseini, A F McDonagh, A L Burlingame and L Z Benet
      Drug Metabolism and Disposition March 1995, 23 (3) 369-376;

  2. Bishop, W P

    1. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides.
      M D Green, W P Bishop and T R Tephly
      Drug Metabolism and Disposition March 1995, 23 (3) 299-302;

  3. Blake, P

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  4. Bradbury, A

    1. Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds.
      P D Worboys, A Bradbury and J B Houston
      Drug Metabolism and Disposition March 1995, 23 (3) 393-397;

  5. Brendel, K

    1. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine. Comparison with rat liver slices and cyclosporin A metabolism.
      A E Vickers, R L Fisher, K Brendel, J Guertler, R Dannecker, B Keller and V Fischer
      Drug Metabolism and Disposition March 1995, 23 (3) 327-333;

  6. Brennan, B

    1. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data.
      K A Hayes, B Brennan, R Chenery and J B Houston
      Drug Metabolism and Disposition March 1995, 23 (3) 349-353;

  7. Burlingame, A L

    1. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry.
      A Ding, P Zia-Amirhosseini, A F McDonagh, A L Burlingame and L Z Benet
      Drug Metabolism and Disposition March 1995, 23 (3) 369-376;

C

  1. Chenery, R

    1. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data.
      K A Hayes, B Brennan, R Chenery and J B Houston
      Drug Metabolism and Disposition March 1995, 23 (3) 349-353;

  2. Choudhury, R

    1. Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat.
      R Choudhury and S Singh
      Drug Metabolism and Disposition March 1995, 23 (3) 314-320;

  3. Creveling, C R

    1. Induction of catechol-O-methyltransferase in the luminal epithelium of rat uterus by progesterone: inhibition by RU-486.
      K Inoue and C R Creveling
      Drug Metabolism and Disposition March 1995, 23 (3) 430-432;

  4. Cribb, A E

    1. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.
      A E Cribb, S P Spielberg and G P Griffin
      Drug Metabolism and Disposition March 1995, 23 (3) 406-414;

D

  1. Dannecker, R

    1. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125.
      A E Vickers, E Meyer, R Dannecker, B Keller, R E Tynes and G Maurer
      Drug Metabolism and Disposition March 1995, 23 (3) 321-326;
    2. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine. Comparison with rat liver slices and cyclosporin A metabolism.
      A E Vickers, R L Fisher, K Brendel, J Guertler, R Dannecker, B Keller and V Fischer
      Drug Metabolism and Disposition March 1995, 23 (3) 327-333;

  2. de Bruijn, E A

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  3. De Sousa, G

    1. Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans.
      F Nicolas, G De Sousa, P Thomas, M Placidi, G Lorenzon and R Rahmani
      Drug Metabolism and Disposition March 1995, 23 (3) 308-313;

  4. Ding, A

    1. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry.
      A Ding, P Zia-Amirhosseini, A F McDonagh, A L Burlingame and L Z Benet
      Drug Metabolism and Disposition March 1995, 23 (3) 369-376;

E

  1. Ellis, A G

    1. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
      L K Webster, A G Ellis, P Kestell and G W Rewcastle
      Drug Metabolism and Disposition March 1995, 23 (3) 363-368;

  2. Escousse, A

    1. Characterization of the in vitro glucuronidation of flurbiprofen enantiomers.
      M Hamdoune, J Mounie, J Magdalou, T Masmoudi, H Goudonnet and A Escousse
      Drug Metabolism and Disposition March 1995, 23 (3) 343-348;

F

  1. Fischer, V

    1. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine. Comparison with rat liver slices and cyclosporin A metabolism.
      A E Vickers, R L Fisher, K Brendel, J Guertler, R Dannecker, B Keller and V Fischer
      Drug Metabolism and Disposition March 1995, 23 (3) 327-333;

  2. Fisher, R A

    1. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes.
      T A Kocarek, E G Schuetz, S C Strom, R A Fisher and P S Guzelian
      Drug Metabolism and Disposition March 1995, 23 (3) 415-421;

  3. Fisher, R L

    1. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine. Comparison with rat liver slices and cyclosporin A metabolism.
      A E Vickers, R L Fisher, K Brendel, J Guertler, R Dannecker, B Keller and V Fischer
      Drug Metabolism and Disposition March 1995, 23 (3) 327-333;

G

  1. Goudonnet, H

    1. Characterization of the in vitro glucuronidation of flurbiprofen enantiomers.
      M Hamdoune, J Mounie, J Magdalou, T Masmoudi, H Goudonnet and A Escousse
      Drug Metabolism and Disposition March 1995, 23 (3) 343-348;

  2. Green, M D

    1. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides.
      M D Green, W P Bishop and T R Tephly
      Drug Metabolism and Disposition March 1995, 23 (3) 299-302;

  3. Griffin, G P

    1. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.
      A E Cribb, S P Spielberg and G P Griffin
      Drug Metabolism and Disposition March 1995, 23 (3) 406-414;

  4. Guengerich, F P

    1. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation.
      H Yamazaki, Z Guo and F P Guengerich
      Drug Metabolism and Disposition March 1995, 23 (3) 438-440;

  5. Guertler, J

    1. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine. Comparison with rat liver slices and cyclosporin A metabolism.
      A E Vickers, R L Fisher, K Brendel, J Guertler, R Dannecker, B Keller and V Fischer
      Drug Metabolism and Disposition March 1995, 23 (3) 327-333;

  6. Guo, Z

    1. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation.
      H Yamazaki, Z Guo and F P Guengerich
      Drug Metabolism and Disposition March 1995, 23 (3) 438-440;

  7. Guzelian, P S

    1. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes.
      T A Kocarek, E G Schuetz, S C Strom, R A Fisher and P S Guzelian
      Drug Metabolism and Disposition March 1995, 23 (3) 415-421;

H

  1. Hamdoune, M

    1. Characterization of the in vitro glucuronidation of flurbiprofen enantiomers.
      M Hamdoune, J Mounie, J Magdalou, T Masmoudi, H Goudonnet and A Escousse
      Drug Metabolism and Disposition March 1995, 23 (3) 343-348;

  2. Harper, P G

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  3. Hayes, K A

    1. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data.
      K A Hayes, B Brennan, R Chenery and J B Houston
      Drug Metabolism and Disposition March 1995, 23 (3) 349-353;

  4. Hendrickx, J

    1. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.
      K Lavrijsen, D van Dyck, J van Houdt, J Hendrickx, J Monbaliu, R Woestenborghs, W Meuldermans and J Heykants
      Drug Metabolism and Disposition March 1995, 23 (3) 354-362;

  5. Heykants, J

    1. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.
      K Lavrijsen, D van Dyck, J van Houdt, J Hendrickx, J Monbaliu, R Woestenborghs, W Meuldermans and J Heykants
      Drug Metabolism and Disposition March 1995, 23 (3) 354-362;

  6. Highley, M S

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  7. Honchel, R

    1. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.
      D Lee, C Szumlanski, J Houtman, R Honchel, K Rojas, J Overhauser, E D Wieben and R M Weinshilboum
      Drug Metabolism and Disposition March 1995, 23 (3) 398-405;

  8. Horton, M N

    1. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
      G K Poon, B Walter, P E Lønning, M N Horton and R McCague
      Drug Metabolism and Disposition March 1995, 23 (3) 377-382;

  9. Houston, J B

    1. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data.
      K A Hayes, B Brennan, R Chenery and J B Houston
      Drug Metabolism and Disposition March 1995, 23 (3) 349-353;
    2. Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds.
      P D Worboys, A Bradbury and J B Houston
      Drug Metabolism and Disposition March 1995, 23 (3) 393-397;

  10. Houtman, J

    1. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.
      D Lee, C Szumlanski, J Houtman, R Honchel, K Rojas, J Overhauser, E D Wieben and R M Weinshilboum
      Drug Metabolism and Disposition March 1995, 23 (3) 398-405;

I

  1. Inoue, K

    1. Induction of catechol-O-methyltransferase in the luminal epithelium of rat uterus by progesterone: inhibition by RU-486.
      K Inoue and C R Creveling
      Drug Metabolism and Disposition March 1995, 23 (3) 430-432;

J

  1. Jones, A D

    1. Biliary excretion of pyrrolic metabolites of [14C]monocrotaline in the rat.
      M W Lamé, A D Jones, D Morin, H J Segall and D W Wilson
      Drug Metabolism and Disposition March 1995, 23 (3) 422-429;

K

  1. Kaminski, D R

    1. Sulfation and glucuronidation of acetaminophen by human hepatocytes cultured on Matrigel and type 1 collagen reproduces conjugation in vivo.
      R E Kane, A P Li and D R Kaminski
      Drug Metabolism and Disposition March 1995, 23 (3) 303-307;

  2. Kane, R E

    1. Sulfation and glucuronidation of acetaminophen by human hepatocytes cultured on Matrigel and type 1 collagen reproduces conjugation in vivo.
      R E Kane, A P Li and D R Kaminski
      Drug Metabolism and Disposition March 1995, 23 (3) 303-307;

  3. Keller, B

    1. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125.
      A E Vickers, E Meyer, R Dannecker, B Keller, R E Tynes and G Maurer
      Drug Metabolism and Disposition March 1995, 23 (3) 321-326;
    2. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine. Comparison with rat liver slices and cyclosporin A metabolism.
      A E Vickers, R L Fisher, K Brendel, J Guertler, R Dannecker, B Keller and V Fischer
      Drug Metabolism and Disposition March 1995, 23 (3) 327-333;

  4. Kestell, P

    1. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
      L K Webster, A G Ellis, P Kestell and G W Rewcastle
      Drug Metabolism and Disposition March 1995, 23 (3) 363-368;

  5. Kocarek, T A

    1. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes.
      T A Kocarek, E G Schuetz, S C Strom, R A Fisher and P S Guzelian
      Drug Metabolism and Disposition March 1995, 23 (3) 415-421;

L

  1. Lamé, M W

    1. Biliary excretion of pyrrolic metabolites of [14C]monocrotaline in the rat.
      M W Lamé, A D Jones, D Morin, H J Segall and D W Wilson
      Drug Metabolism and Disposition March 1995, 23 (3) 422-429;

  2. Lavrijsen, K

    1. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.
      K Lavrijsen, D van Dyck, J van Houdt, J Hendrickx, J Monbaliu, R Woestenborghs, W Meuldermans and J Heykants
      Drug Metabolism and Disposition March 1995, 23 (3) 354-362;

  3. Lee, D

    1. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.
      D Lee, C Szumlanski, J Houtman, R Honchel, K Rojas, J Overhauser, E D Wieben and R M Weinshilboum
      Drug Metabolism and Disposition March 1995, 23 (3) 398-405;

  4. Li, A P

    1. Sulfation and glucuronidation of acetaminophen by human hepatocytes cultured on Matrigel and type 1 collagen reproduces conjugation in vivo.
      R E Kane, A P Li and D R Kaminski
      Drug Metabolism and Disposition March 1995, 23 (3) 303-307;

  5. Lønning, P E

    1. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
      G K Poon, B Walter, P E Lønning, M N Horton and R McCague
      Drug Metabolism and Disposition March 1995, 23 (3) 377-382;

  6. Lorenzon, G

    1. Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans.
      F Nicolas, G De Sousa, P Thomas, M Placidi, G Lorenzon and R Rahmani
      Drug Metabolism and Disposition March 1995, 23 (3) 308-313;

M

  1. Maes, R A

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  2. Magdalou, J

    1. Characterization of the in vitro glucuronidation of flurbiprofen enantiomers.
      M Hamdoune, J Mounie, J Magdalou, T Masmoudi, H Goudonnet and A Escousse
      Drug Metabolism and Disposition March 1995, 23 (3) 343-348;

  3. Mansi, J

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  4. Masmoudi, T

    1. Characterization of the in vitro glucuronidation of flurbiprofen enantiomers.
      M Hamdoune, J Mounie, J Magdalou, T Masmoudi, H Goudonnet and A Escousse
      Drug Metabolism and Disposition March 1995, 23 (3) 343-348;

  5. Mather, L E

    1. Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep. Importance of the kidney.
      R W Milne, C F McLean, L E Mather, R L Nation, W B Runciman, A J Rutten and A A Somogyi
      Drug Metabolism and Disposition March 1995, 23 (3) 334-342;

  6. Maurer, G

    1. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125.
      A E Vickers, E Meyer, R Dannecker, B Keller, R E Tynes and G Maurer
      Drug Metabolism and Disposition March 1995, 23 (3) 321-326;

  7. McCague, R

    1. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
      G K Poon, B Walter, P E Lønning, M N Horton and R McCague
      Drug Metabolism and Disposition March 1995, 23 (3) 377-382;

  8. McDonagh, A F

    1. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry.
      A Ding, P Zia-Amirhosseini, A F McDonagh, A L Burlingame and L Z Benet
      Drug Metabolism and Disposition March 1995, 23 (3) 369-376;

  9. McLean, C F

    1. Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep. Importance of the kidney.
      R W Milne, C F McLean, L E Mather, R L Nation, W B Runciman, A J Rutten and A A Somogyi
      Drug Metabolism and Disposition March 1995, 23 (3) 334-342;

  10. Meuldermans, W

    1. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.
      K Lavrijsen, D van Dyck, J van Houdt, J Hendrickx, J Monbaliu, R Woestenborghs, W Meuldermans and J Heykants
      Drug Metabolism and Disposition March 1995, 23 (3) 354-362;

  11. Meyer, E

    1. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125.
      A E Vickers, E Meyer, R Dannecker, B Keller, R E Tynes and G Maurer
      Drug Metabolism and Disposition March 1995, 23 (3) 321-326;

  12. Milne, R W

    1. Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep. Importance of the kidney.
      R W Milne, C F McLean, L E Mather, R L Nation, W B Runciman, A J Rutten and A A Somogyi
      Drug Metabolism and Disposition March 1995, 23 (3) 334-342;

  13. Mizsak, S A

    1. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase.
      L C Wienkers, R C Steenwyk, S A Mizsak and P G Pearson
      Drug Metabolism and Disposition March 1995, 23 (3) 383-392;

  14. Momerency, G

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  15. Monbaliu, J

    1. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.
      K Lavrijsen, D van Dyck, J van Houdt, J Hendrickx, J Monbaliu, R Woestenborghs, W Meuldermans and J Heykants
      Drug Metabolism and Disposition March 1995, 23 (3) 354-362;

  16. Morin, D

    1. Biliary excretion of pyrrolic metabolites of [14C]monocrotaline in the rat.
      M W Lamé, A D Jones, D Morin, H J Segall and D W Wilson
      Drug Metabolism and Disposition March 1995, 23 (3) 422-429;

  17. Mounie, J

    1. Characterization of the in vitro glucuronidation of flurbiprofen enantiomers.
      M Hamdoune, J Mounie, J Magdalou, T Masmoudi, H Goudonnet and A Escousse
      Drug Metabolism and Disposition March 1995, 23 (3) 343-348;

N

  1. Nation, R L

    1. Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep. Importance of the kidney.
      R W Milne, C F McLean, L E Mather, R L Nation, W B Runciman, A J Rutten and A A Somogyi
      Drug Metabolism and Disposition March 1995, 23 (3) 334-342;

  2. Nicolas, F

    1. Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans.
      F Nicolas, G De Sousa, P Thomas, M Placidi, G Lorenzon and R Rahmani
      Drug Metabolism and Disposition March 1995, 23 (3) 308-313;

O

  1. Overhauser, J

    1. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.
      D Lee, C Szumlanski, J Houtman, R Honchel, K Rojas, J Overhauser, E D Wieben and R M Weinshilboum
      Drug Metabolism and Disposition March 1995, 23 (3) 398-405;

P

  1. Pearson, P G

    1. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase.
      L C Wienkers, R C Steenwyk, S A Mizsak and P G Pearson
      Drug Metabolism and Disposition March 1995, 23 (3) 383-392;

  2. Placidi, M

    1. Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans.
      F Nicolas, G De Sousa, P Thomas, M Placidi, G Lorenzon and R Rahmani
      Drug Metabolism and Disposition March 1995, 23 (3) 308-313;

  3. Poon, G K

    1. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
      G K Poon, B Walter, P E Lønning, M N Horton and R McCague
      Drug Metabolism and Disposition March 1995, 23 (3) 377-382;

R

  1. Rahmani, R

    1. Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans.
      F Nicolas, G De Sousa, P Thomas, M Placidi, G Lorenzon and R Rahmani
      Drug Metabolism and Disposition March 1995, 23 (3) 308-313;

  2. Rewcastle, G W

    1. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
      L K Webster, A G Ellis, P Kestell and G W Rewcastle
      Drug Metabolism and Disposition March 1995, 23 (3) 363-368;

  3. Rojas, K

    1. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.
      D Lee, C Szumlanski, J Houtman, R Honchel, K Rojas, J Overhauser, E D Wieben and R M Weinshilboum
      Drug Metabolism and Disposition March 1995, 23 (3) 398-405;

  4. Runciman, W B

    1. Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep. Importance of the kidney.
      R W Milne, C F McLean, L E Mather, R L Nation, W B Runciman, A J Rutten and A A Somogyi
      Drug Metabolism and Disposition March 1995, 23 (3) 334-342;

  5. Rutten, A J

    1. Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep. Importance of the kidney.
      R W Milne, C F McLean, L E Mather, R L Nation, W B Runciman, A J Rutten and A A Somogyi
      Drug Metabolism and Disposition March 1995, 23 (3) 334-342;

S

  1. Schuetz, E G

    1. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes.
      T A Kocarek, E G Schuetz, S C Strom, R A Fisher and P S Guzelian
      Drug Metabolism and Disposition March 1995, 23 (3) 415-421;

  2. Segall, H J

    1. Biliary excretion of pyrrolic metabolites of [14C]monocrotaline in the rat.
      M W Lamé, A D Jones, D Morin, H J Segall and D W Wilson
      Drug Metabolism and Disposition March 1995, 23 (3) 422-429;

  3. Singh, S

    1. Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat.
      R Choudhury and S Singh
      Drug Metabolism and Disposition March 1995, 23 (3) 314-320;

  4. Somogyi, A A

    1. Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep. Importance of the kidney.
      R W Milne, C F McLean, L E Mather, R L Nation, W B Runciman, A J Rutten and A A Somogyi
      Drug Metabolism and Disposition March 1995, 23 (3) 334-342;

  5. Spielberg, S P

    1. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.
      A E Cribb, S P Spielberg and G P Griffin
      Drug Metabolism and Disposition March 1995, 23 (3) 406-414;

  6. Steenwyk, R C

    1. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase.
      L C Wienkers, R C Steenwyk, S A Mizsak and P G Pearson
      Drug Metabolism and Disposition March 1995, 23 (3) 383-392;

  7. Strom, S C

    1. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes.
      T A Kocarek, E G Schuetz, S C Strom, R A Fisher and P S Guzelian
      Drug Metabolism and Disposition March 1995, 23 (3) 415-421;

  8. Szumlanski, C

    1. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.
      D Lee, C Szumlanski, J Houtman, R Honchel, K Rojas, J Overhauser, E D Wieben and R M Weinshilboum
      Drug Metabolism and Disposition March 1995, 23 (3) 398-405;

T

  1. Tephly, T R

    1. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides.
      M D Green, W P Bishop and T R Tephly
      Drug Metabolism and Disposition March 1995, 23 (3) 299-302;

  2. Thomas, P

    1. Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans.
      F Nicolas, G De Sousa, P Thomas, M Placidi, G Lorenzon and R Rahmani
      Drug Metabolism and Disposition March 1995, 23 (3) 308-313;

  3. Tynes, R E

    1. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125.
      A E Vickers, E Meyer, R Dannecker, B Keller, R E Tynes and G Maurer
      Drug Metabolism and Disposition March 1995, 23 (3) 321-326;

V

  1. Van Cauwenberghe, K

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  2. van Dyck, D

    1. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.
      K Lavrijsen, D van Dyck, J van Houdt, J Hendrickx, J Monbaliu, R Woestenborghs, W Meuldermans and J Heykants
      Drug Metabolism and Disposition March 1995, 23 (3) 354-362;

  3. van Houdt, J

    1. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.
      K Lavrijsen, D van Dyck, J van Houdt, J Hendrickx, J Monbaliu, R Woestenborghs, W Meuldermans and J Heykants
      Drug Metabolism and Disposition March 1995, 23 (3) 354-362;

  4. Van Oosterom, A T

    1. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans.
      M S Highley, G Momerency, K Van Cauwenberghe, A T Van Oosterom, E A de Bruijn, R A Maes, P Blake, J Mansi and P G Harper
      Drug Metabolism and Disposition March 1995, 23 (3) 433-437;

  5. Vickers, A E

    1. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125.
      A E Vickers, E Meyer, R Dannecker, B Keller, R E Tynes and G Maurer
      Drug Metabolism and Disposition March 1995, 23 (3) 321-326;
    2. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine. Comparison with rat liver slices and cyclosporin A metabolism.
      A E Vickers, R L Fisher, K Brendel, J Guertler, R Dannecker, B Keller and V Fischer
      Drug Metabolism and Disposition March 1995, 23 (3) 327-333;

W

  1. Walter, B

    1. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
      G K Poon, B Walter, P E Lønning, M N Horton and R McCague
      Drug Metabolism and Disposition March 1995, 23 (3) 377-382;

  2. Webster, L K

    1. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
      L K Webster, A G Ellis, P Kestell and G W Rewcastle
      Drug Metabolism and Disposition March 1995, 23 (3) 363-368;

  3. Weinshilboum, R M

    1. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.
      D Lee, C Szumlanski, J Houtman, R Honchel, K Rojas, J Overhauser, E D Wieben and R M Weinshilboum
      Drug Metabolism and Disposition March 1995, 23 (3) 398-405;

  4. Wieben, E D

    1. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.
      D Lee, C Szumlanski, J Houtman, R Honchel, K Rojas, J Overhauser, E D Wieben and R M Weinshilboum
      Drug Metabolism and Disposition March 1995, 23 (3) 398-405;

  5. Wienkers, L C

    1. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase.
      L C Wienkers, R C Steenwyk, S A Mizsak and P G Pearson
      Drug Metabolism and Disposition March 1995, 23 (3) 383-392;

  6. Wilson, D W

    1. Biliary excretion of pyrrolic metabolites of [14C]monocrotaline in the rat.
      M W Lamé, A D Jones, D Morin, H J Segall and D W Wilson
      Drug Metabolism and Disposition March 1995, 23 (3) 422-429;

  7. Woestenborghs, R

    1. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.
      K Lavrijsen, D van Dyck, J van Houdt, J Hendrickx, J Monbaliu, R Woestenborghs, W Meuldermans and J Heykants
      Drug Metabolism and Disposition March 1995, 23 (3) 354-362;

  8. Worboys, P D

    1. Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds.
      P D Worboys, A Bradbury and J B Houston
      Drug Metabolism and Disposition March 1995, 23 (3) 393-397;

Y

  1. Yamazaki, H

    1. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation.
      H Yamazaki, Z Guo and F P Guengerich
      Drug Metabolism and Disposition March 1995, 23 (3) 438-440;

Z

  1. Zia-Amirhosseini, P

    1. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry.
      A Ding, P Zia-Amirhosseini, A F McDonagh, A L Burlingame and L Z Benet
      Drug Metabolism and Disposition March 1995, 23 (3) 369-376;
Back to top

In this issue